Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $232,800.00 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total transaction of $232,800.00. Following the completion of the sale, the executive vice president now directly owns 317,716 shares of the company’s stock, valued at approximately $7,396,428.48. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

BioLife Solutions Price Performance

Shares of BioLife Solutions stock opened at $23.63 on Friday. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04. BioLife Solutions, Inc. has a 12 month low of $8.92 and a 12 month high of $26.73. The stock has a 50 day moving average of $24.60 and a 200 day moving average of $21.76. The firm has a market cap of $1.09 billion, a PE ratio of -16.64 and a beta of 1.88.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.08. BioLife Solutions had a negative return on equity of 10.75% and a negative net margin of 59.88%. The firm had revenue of $28.33 million during the quarter, compared to the consensus estimate of $23.80 million. On average, research analysts expect that BioLife Solutions, Inc. will post -0.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. TD Cowen upped their target price on shares of BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, July 17th. Craig Hallum upped their price objective on BioLife Solutions from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Northland Securities lifted their target price on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, HC Wainwright began coverage on shares of BioLife Solutions in a research report on Monday, September 30th. They set a “buy” rating and a $29.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $26.67.

Institutional Trading of BioLife Solutions

A number of large investors have recently made changes to their positions in BLFS. 1620 Investment Advisors Inc. bought a new position in shares of BioLife Solutions in the 2nd quarter valued at about $35,000. Isthmus Partners LLC lifted its stake in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 42,265 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares during the period. Register Financial Advisors LLC purchased a new position in shares of BioLife Solutions in the 1st quarter worth approximately $96,000. Finally, Canada Pension Plan Investment Board purchased a new stake in BioLife Solutions during the 2nd quarter valued at $122,000. 93.24% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.